Skip to main content
无锡晶海 logo

无锡晶海 — Investor Relations & Filings

Ticker · 920547 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2024-09-09 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920547

About 无锡晶海

https://www.chinaaminoacid.com/

Wuxi Jinghai Amino Acid Co., Ltd. specializes in the research, development, and large-scale production of high-purity amino acids through microbial fermentation. The company’s core product portfolio includes L-Isoleucine, L-Valine, L-Leucine, L-Proline, and L-Threonine, which serve as critical raw materials for the pharmaceutical, nutritional, and food processing sectors. Utilizing advanced biotechnological processes, the firm maintains rigorous quality control standards, holding certifications such as GMP, ISO, HALAL, and KOSHER. Its products are primarily utilized in the formulation of parenteral nutrition, specialized medical foods, and high-end supplements. The company focuses on technological innovation to optimize fermentation yields and purity levels, positioning itself as a key supplier in the global amino acid supply chain.

Recent filings

Filing Released Lang Actions
2024年第五次临时股东大会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2024 fifth extraordinary shareholders meeting of Wuxi Jinghai Amino Acid Co., Ltd. It details the meeting attendance, voting results on board and supervisory committee member elections, and the legal opinion on the meeting's compliance. The content focuses on the election and appointment of directors and supervisors, with voting results and legal validation. There is no financial data, earnings, or report publication mentioned. The document is an official announcement of voting results from a shareholders meeting, specifically about board and supervisory appointments. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4112 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2024-09-09 Chinese
关于持续督导保荐机构主体变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor institution for the company Wuxi Jinghai Amino Acid Co., Ltd. It details the merger of the original sponsor institution into another entity and the continuation of business under the new entity. There is no financial data, no report attached or referenced as being published, and no mention of voting results or management changes. This is a regulatory announcement about a sponsor institution change, which does not fit into categories like Annual Report, Interim Report, or Management Information. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-09-05 Chinese
关于募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the delay of a fundraising investment project by Wuxi Jinghai Amino Acid Co., Ltd. It details the fundraising amount, usage of funds, reasons for the delay, and the impact on the company. It includes references to regulatory approvals and audit reports related to the fundraising but does not contain financial statements or detailed financial performance data. The document is primarily about the update on the use of raised capital and project progress, which fits the category of a Capital/Financing Update rather than a full financial report or audit report. The document length is 2543 characters, which is relatively short and focused on the fundraising project update, not a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-08-21 Chinese
2024年第一次职工代表大会决议
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 2024 first employee representative meeting of Wuxi Jinghai Amino Acid Co., Ltd. It details the meeting date, attendance, and voting results on board and supervisory committee elections. There is no financial data, earnings information, or report publication mentioned. The content focuses on board and supervisory committee changes, which aligns with announcements about changes in the company's board or senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification, so those categories are excluded.
2024-08-21 Chinese
关于召开2024年第五次临时股东大会会议通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2024 fifth extraordinary general meeting of shareholders for Wuxi Jinghai Amino Acid Co., Ltd. It details the meeting date, voting methods, agenda items including board and supervisory committee elections, and procedural information for shareholders. There is no financial data, earnings, or report content included. The document is primarily an announcement about the meeting and its agenda, not a report or results announcement. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and not the voting results or proxy materials, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and it is not a report publication announcement. Hence, the classification is PSI with high confidence.
2024-08-21 Chinese
关于公司取得原料药CEP证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Wuxi Jinghai Amino Acid Co., Ltd. regarding the receipt of a CEP certificate for a raw material drug (Lysine Acetate) issued by the European Directorate for the Quality of Medicines (EDQM). It describes the certificate details, the drug's properties, and the potential impact on the company. The document is short (960 characters) and serves as a regulatory announcement about a certification achievement rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-08-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.